Ketamine for Bipolar Disorder

19 papers and 36 clinical trials exploring ketamine as a treatment for bipolar disorder.

CompoundArylcyclohexylamine

Ketamine

A dissociative anesthetic with rapid-acting antidepressant properties, widely used in clinical settings for mood and pain disorders.

Full Ketamine profile
Indication45 million worldwide

Bipolar Disorder

Bipolar disorder, characterised by extreme fluctuations in mood, is a complex mental health condition that affects approximately 45 million people worldwide. Current research on psychedelics as a potential treatment is limited due to concerns about inducing manic episodes, but emerging evidence, particularly regarding ketamine, suggests promise for alleviating depressive symptoms associated with the disorder.

Full Bipolar Disorder profile

Academic Research

19 papers
Paywallindividual

Pain mediates the improvement of social functions of repeated intravenous ketamine in patients with unipolar and bipolar depression

This re-analysis of an open-label study (n=103) investigated the effects of ketamine (35mg/70kg, 6x) on pain, depression, and social function in patients with bipolar or unipolar depressive disorder. The results showed that ketamine treatment significantly improved psychosocial functioning and reduced pain index. Mediation analysis revealed that the severity of depressive symptoms and the affective index of pain partially mediated the association between ketamine treatment and improvements in subjective and objective social functioning.

Published
Journal
Journal of Affective Disorders
Authors
Gan, Y., Hu, Z., Lan, X-F., Li, N., Li, W., Liu, H., Ning, Y-P., Wang, C., Wu, Z., Ye, Y., Zhang, F., Zhou, Y.
Paywallindividual

Real World Effectiveness of Repeated Ketamine Infusions for Treatment Resistant Bipolar Depression

In a real‑world observational cohort of 66 patients with treatment‑resistant bipolar I/II depression, four sub‑anaesthetic intravenous ketamine infusions over two weeks produced statistically and clinically significant, progressive reductions in depressive symptoms, suicidality and anxiety (mean QIDS‑SR16 reduction 6.08; p<0.0001). Response and remission rates were 35% and 20% respectively, with generally good tolerability (4.5% treatment‑emergent hypomania, no mania or psychosis).

Published
Journal
Bipolar Disorders
Authors
Chau, E. H., Di Vincenzo, J. D., Fancy, F., Gill, H., Husain, M. I., McIntyre, R. S., Mckenzie, A., Phan, L., Rodrigues, N. B., Rosenblat, J. D., Sethi, A., Tabassum, A.
Paywallindividual

Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression

This open-label study (n=70) on suicidal ideation (SI) in patients with major depressive disorder (MDD) and bipolar depression (BD) finds that esketamine (1x p/w 6ws) led to significant reductions in SI at the end of the study (24h after last administration). There was no statistically significant difference between the two subpopulations.

Published
Journal
Clinical Drug Investigation
Authors
Abdo, G. L., Barbosa, M. G., De Oliveira Cerqueira, R., Del Porto, J. A., Del Sant, L. C., Delfino, S. R., Fava, V. A. R., Grossi, J. D., Lacerda, A. L. T., Lucchese, C., Magalhães, E., Nakahira, C., Sarin, L. M., Steglich, M., Surjan, J., Tuena, M. A.

Clinical Trials

36 trials

Explore further

Search all Ketamine papers Search all Bipolar Disorder trials Full Ketamine profile Full Bipolar Disorder profile